演示文稿

Understanding and Tackling Obesity: Pub Date : 2020-10-07 DOI:10.4324/9781003072454-4

Ruth M. MacConville

{"title":"演示文稿","authors":"Ruth M. MacConville","doi":"10.4324/9781003072454-4","DOIUrl":null,"url":null,"abstract":"The novel PARP1-selective inhibitor AZD5305 has reduced haematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models Sonja J. Gill1, Ruth Macdonald1, Carmen Pin1, Rob Collins1, Emilyanne Leonard1, Gareth Maglennon1, Andy Pike2, Peter Cotton1, Glen Hawthorn1, Jordan Pugh1, Rebecca Sargeant1, Daniel Sutton1, James Atkinson1, Stewart Jones1, Sarah Chinery1, Mark Anderton1. Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK1, DMPK, Oncology R&D, AstraZeneca, Cambridge, UK2","PeriodicalId":108604,"journal":{"name":"Understanding and Tackling Obesity:","volume":"29 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PowerPoint Presentation\",\"authors\":\"Ruth M. MacConville\",\"doi\":\"10.4324/9781003072454-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The novel PARP1-selective inhibitor AZD5305 has reduced haematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models Sonja J. Gill1, Ruth Macdonald1, Carmen Pin1, Rob Collins1, Emilyanne Leonard1, Gareth Maglennon1, Andy Pike2, Peter Cotton1, Glen Hawthorn1, Jordan Pugh1, Rebecca Sargeant1, Daniel Sutton1, James Atkinson1, Stewart Jones1, Sarah Chinery1, Mark Anderton1. Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK1, DMPK, Oncology R&D, AstraZeneca, Cambridge, UK2\",\"PeriodicalId\":108604,\"journal\":{\"name\":\"Understanding and Tackling Obesity:\",\"volume\":\"29 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-10-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Understanding and Tackling Obesity:\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4324/9781003072454-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Understanding and Tackling Obesity:","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4324/9781003072454-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

与PARP1/2抑制剂相比，新型parp1选择性抑制剂AZD5305在临床前模型Sonja J. Gill1、Ruth Macdonald1、Carmen Pin1、Rob Collins1、Emilyanne Leonard1、Gareth Maglennon1、Andy Pike2、Peter Cotton1、Glen hawthor1、Jordan Pugh1、Rebecca Sargeant1、Daniel Sutton1、James Atkinson1、Stewart Jones1、Sarah Chinery1、Mark Anderton1中降低了血液毒性。临床药理学和安全科学，研发，阿斯利康，剑桥，英国1;DMPK，肿瘤研发，阿斯利康，剑桥，英国2

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PowerPoint Presentation

The novel PARP1-selective inhibitor AZD5305 has reduced haematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models Sonja J. Gill1, Ruth Macdonald1, Carmen Pin1, Rob Collins1, Emilyanne Leonard1, Gareth Maglennon1, Andy Pike2, Peter Cotton1, Glen Hawthorn1, Jordan Pugh1, Rebecca Sargeant1, Daniel Sutton1, James Atkinson1, Stewart Jones1, Sarah Chinery1, Mark Anderton1. Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK1, DMPK, Oncology R&D, AstraZeneca, Cambridge, UK2

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Understanding and Tackling Obesity:

自引率

0.00%

发文量